| Identification | Back Directory | [Name]
Cefozopran hydrochloride | [CAS]
113981-44-5 | [Synonyms]
Czop
D02233
Firstcin (tn)
Cefozopran hydrochlo
SCE-2787 hydrochloride
Cefozopran hydrochloride
Cefozopran hydrochloride (jp15)
Cefozopran hydrochloride USP/EP/BP
(6R,7R)-7-[[(2E)-2-(5-Amino-1,2,4-thiadiazol-3-yl)-2-methoxyiminoacetyl]amino]-3-(imidazo[2,3-f]pyridazin-4-ium-1-ylmethyl)-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid chloride | [EINECS(EC#)]
1806241-263-5 | [Molecular Formula]
C19H17N9O5S2.HCl | [MDL Number]
MFCD00944908 | [MOL File]
113981-44-5.mol | [Molecular Weight]
551.99 |
| Chemical Properties | Back Directory | [storage temp. ]
under inert gas (nitrogen or Argon) at 2-8°C | [form ]
Solid | [color ]
White to light yellow | [Water Solubility ]
Water : ≥ 52 mg/mL (94.20 mM) |
| Hazard Information | Back Directory | [Antimicrobial activity]
Cefazolam hydrochloride is suitable for Staphylococcus, Streptococcus, Enterococcus, Peptostreptococcus, Escherichia coli, Enterobacter, Serratia, Klebsiella, Citrobacter, Proteus, Pseudomonas, Influenza Bacillus, Acinetobacter, Bacteroidetes, septicemia caused by sensitive bacteria to cefazolam hydrochloride, trauma infection, respiratory system, urinary system and abdominal cavity, pelvic purulent inflammation, ophthalmology and ENT inflammation, etc. | [Biological Activity]
Cefozopran (SCE-2787) hydrochloride is a semi-synthetic, parenteral, fourth-generation cephalosporin. As an antibiotic, it has broad-spectrum antibacterial activity and can inhibit most Gram-negative and Gram-positive bacteria. | [in vitro]
Cefozopran (SCE-2787) is a fourth-generation cephalosporin that has good activity against gram-positive organisms including methicillin-susceptible staphylococci, enterococci, and viridans group streptococci; and against gram-negative organisms including hemophilus influenza. Moreover, cefozopran has comparatively good activity against enterococci and P. aeruginosa , which are refractory to other cephalosporins. | [in vivo]
Cefozopran (SCE-2787) (5-80 mg/kg; sc; twice a day for 5 days; four-week-old ICR male mice) is effective against acute respiratory tract infections caused by Kiebsiella pneumonia DT-S. In the model of chronic respiratory tract infection caused by K. pneumoniae 27, Cefozopran (20-80 mg/kg; sc; twice a day for 7 days; five-week-old CBA/J female mice) is as effective as Ceftazidime. |
|
|